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Combinations of capecitabine and a taxane are highly active in metastatic breast cancer, and synergy between 
capecitabine and docetaxel has also been demonstrated. Such combinations potentially would provide a prom-
ising non–anthracycline-based alternative for patients with early breast cancer. Non-anthracycline preoperative 
regimens are a particularly interesting proposition in human epidermal growth factor receptor 2 (HER2)-positive 
breast cancer, as they offer less cardiotoxicity and thus can be used concomitantly with preoperative trastuzumab 
therapy. Capecitabine plus docetaxel (XT) and trastuzumab with XT (HXT) are promising non-anthracycline 
regimens for the preoperative treatment of women with HER2-negative and HER2-positive breast cancer, re-
spectively. The Xeloda in Neoadjuvant (XeNA) trial, an open-label, multicenter, phase II study, independently 
assesses the efficacy of preoperative XT in HER2-negative and HXT in HER2-positive breast cancer. A particu-
larly important feature of the XeNA study is the use of pathologic complete response (pCR) plus near pCR 
(npCR) as the primary endpoint. pCR is associated with long-term survival, and although it is valuable as a sur-
rogate marker, pCR has some limitations. Measurement of residual breast cancer burden (RCB) has been pro-
posed as a more practical alternative to predict survival after preoperative chemotherapy. The combination of 
RCB-0 and RCB-I (npCR) expands the subset of patients shown to benefit from preoperative chemotherapy, and 
achievement of pCR or npCR is associated with long disease-free survival. In XeNA, the sum of pCR and npCR 
will facilitate correlative studies designed to identify patients most likely to benefit from XT and HXT and may 
expedite the clinical evaluation of these novel preoperative regimens. 
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INTRODUCTION 
Primary administration of systemic chemother-
apy is standard of care for locally advanced breast 
cancer (LABC) [1]. In women with large operable tu-
mors, preoperative administration might increase the 
likelihood of breast-conserving surgery [2]. Several 
randomized trials comparing preoperative versus 
postoperative treatment have shown equivalent dis-
ease-free survival (DFS) and overall survival (OS) [3]. 
Although pathologic stage may not correlate perfectly 
with DFS and OS, the value of findings from preop-
erative chemotherapy outweighs this disadvantage. 
Preoperative treatment serves as an excellent in vivo 
model, providing prognostic and potentially predic-
tive information and facilitating the evaluation of tu-
mor biomarkers to improve individualization of 
therapeutic strategies [4]. This may expedite the clini-
cal development of new drugs and regimens.  
Pathologic response and clinical outcomes 
Pathologic complete response (pCR) is associated 
with long-term survival [2,5-9]. However, despite its 
value as a surrogate marker, pCR has some limitations 
a s  a n  e n d p o i n t  b e c a u s e  o f  t h e  v a r i e t y  i n  d e f i n i t i o n s  
between studies [10]. An international panel recom-
mended that pCR must not include any residual inva-
sive or in situ cancer in the breast or lymph nodes [1], 
but it has been argued that such a restrictive and purist 
definition weakens the clinical utility of this endpoint 
and diminishes the number of informative patients 
[11]. Int. J. Med. Sci. 2008, 5 
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An interesting concept with important clinical 
implications is the attainment of significant tumor 
downsizing to microscopic levels only. Patients with 
small (T1a-b), node-negative breast tumors have ex-
cellent rates of long-term relapse-free survival (91% at 
10 years and 87% at 20 years) [12]. Measurement of 
residual breast cancer burden (RCB) has also been 
proposed as a practical alternative to the traditional 
dichotomy between pCR and residual disease to pre-
dict survival after preoperative chemotherapy (Figure 
1) [13,14]. The combination of RCB-0 (pCR or Ameri-
can Joint Committee on Cancer stage 0 [15]) and RCB-I 
(near pCR [npCR]) expands the subset of patients 
shown to benefit from preoperative chemotherapy. 
Achievement of pCR or npCR is associated with long 
DFS, whereas moderate or extensive residual disease 
predicts for short DFS. Based on these data, reduction 
of the initial tumor size to T1a is used to define npCR 
in the Xeloda in NeoAdjuvant (XeNA) study of pre-
operative chemotherapy described below. 
 
 
 
Figure 1: Likelihood of distant relapse in patients with residual 
cancer burden (RCB) -0 (pCR), RCB-I (npCR, minimal residual 
disease), RCB-II (moderate residual disease), or RCB-III (ex-
tensive residual disease). P value is from a log-rank test for 
difference between all survival curves. RCB is calculated as a 
continuous index combining pathologic measurements of pri-
mary tumor (size and cellularity) and nodal metastases (number 
and size) to predict distant relapse-free survival (calculator 
available online at: http://www.mdanderson.org/breastcancer_ 
RCB). Reproduced with permission from Symmans et al. 2007 
[13]. 
 
Capecitabine plus docetaxel for early BC 
Adding a taxane to anthracycline-based preop-
erative chemotherapy significantly improves overall 
response rates (ORR) and pCR rates [8,16]. Combina-
tions of capecitabine and a taxane are highly active in 
metastatic breast cancer (MBC) [17] and provide a 
promising non-anthracycline-based alternative for 
patients with early breast cancer with the advantage of 
potentially less cardiotoxicity [18]. 
Capecitabine is an oral fluoropyrimidine de-
signed to deliver 5-fluorouracil (5-FU) selectively to 
tumor sites by exploiting higher concentrations of 
thymidine phosphorylase (TP) in malignant cells 
compared with normal cells [19]. TP activity is 
upregulated by several chemotherapeutic agents, in-
cluding taxanes, providing an elegant explanation for 
the preclinical synergy between capecitabine and do-
cetaxel [20-22]. TP expression may also be a predictive 
marker for the clinical benefit of docetaxel plus cape-
citabine in patients with breast cancer [23]. 
 In a randomized trial in patients with MBC, the 
combination of capecitabine 1250 mg/m2 twice daily 
(BID) on days 1-14 plus docetaxel 75 mg/m2 on day 1 
(XT) significantly improved OS (hazard ratio, 0.775; 
95% confidence interval [CI], 0.634-0.947) compared 
with docetaxel alone [17]. Gastrointestinal side effects 
and hand-foot syndrome were more common with XT, 
whereas myalgia, arthralgia, and neutropenic fe-
ver/sepsis were more common with single-agent do-
cetaxel. Based on clinical experience and findings from 
retrospective analyses of dose modification in this trial, 
lower doses of capecitabine and docetaxel are typically 
used in this setting and do not appear to reduce effi-
cacy [24,25]. The high activity and manageable safety 
profile of XT given at appropriate doses in the metas-
tatic setting provided the rationale for evaluating XT in 
early breast cancer [26]. 
In a phase III trial, 209 women with axillary 
node-positive, stage II/III breast cancer were ran-
domly allocated to receive four 3-weekly cycles of 
preoperative XT (capecitabine 1000 mg/m2 BID on 
days 1-14 and docetaxel 75 mg/m2 on day 1) or AC 
(doxorubicin 60 mg/m2 and cyclophosphamide 600 
mg/m2 on day 1) [18]. XT significantly increased pCR 
rate (21% vs. 10%, respectively, P = 0.024) and ORR 
(84% vs. 65%, respectively, P = 0.003). Of note, the pCR 
rate achieved with XT was within the range seen with 
anthracycline-taxane sequential therapy in a mixed 
population of patients (human epidermal growth fac-
tor receptor [HER]2 negative and positive) [8]. Since 
most of the published preoperative trials used 6 or 8 
cycles of treatment, it was considered important to 
explore the activity of a shorter treatment course (4 
cycles) for both HER2-positive and HER2-negative 
patients. Int. J. Med. Sci. 2008, 5 
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Capecitabine, docetaxel, plus trastuzumab for 
HER2-positive BC  
Non-anthracycline preoperative regimens are a 
particularly interesting proposition in HER2-positive 
breast cancer, because they avoid the risk of anthracy-
cline-induced cardiotoxicity in patients eligible for 
adjuvant or preoperative trastuzumab. The value of 
preoperative trastuzumab plus chemotherapy has 
been demonstrated in several phase II studies 
[9,27-31]. In 42 patients with operable breast cancer, 
adding trastuzumab to preoperative paclitaxel fol-
lowed by 5-FU, epirubicin, and cyclophosphamide 
significantly improved pCR rate compared with che-
motherapy alone (67% vs. 25%, respectively; P = 0.02) 
[30]. 
In vivo data [32] and clinical studies [33-35] have 
demonstrated the efficacy of trastuzumab plus cape-
citabine in HER2-positive breast cancer. A randomized 
phase II study in patients with MBC or LABC com-
pared 3-weekly cycles of HXT (trastuzumab 8 mg/kg 
loading dose followed by 6 mg/kg, capecitabine 950 
mg/m2 BID days 1-14, and docetaxel 75 mg/m2) with 
HT (trastuzumab and docetaxel 100 mg/m2) [36]. Both 
combinations produced high ORR (71% and 73%, re-
spectively), but the HXT combination significantly 
prolonged both time to progression and progres-
sion-free survival compared with HT, with the median 
increased by 5 months for both parameters. Promising 
results were also observed in a phase II study of pre-
operative HXT (trastuzumab, capecitabine 900 mg/m2 
BID, and docetaxel 36 mg/m2 days 1 and 8) adminis-
tered every 3 weeks to patients with HER2-positive 
LABC (or XT alone for patients with HER2-negative 
tumors) [37]. The ORR was 94% and, in patients 
treated with HXT, the pCR rate was 45%. HXT dem-
onstrated good tolerability in these studies: the lower 
XT dose is well tolerated, and HXT may reduce the risk 
of overlapping cardiac toxicity with adjuvant anthra-
cyclines. 
XeNA 
This open-label, multicenter, phase II study uses 
Simon’s optimal two-stage design [38] to independ-
ently assess the efficacy of preoperative XT in 
HER2-negative and HXT in HER2-positive breast 
cancer. The study design was approved by the ethics 
committees at participating institutions, and all pa-
tients provided written informed consent. Enrollment 
of 157 patients was completed in May 2007; 156 pa-
tients (122 HER2-negative and 34 HER2-positive) are 
evaluable. 
Patient Population 
Women  ≥18 years with newly diagnosed, his-
tologically confirmed, infiltrating (invasive), 
HER2-negative or HER2-positive stage II/III breast 
cancer, with no evidence of metastatic disease except 
ipsilateral axillary lymph nodes (T2-3, N0-1, M0), were 
eligible for the study provided that they had not pre-
viously received any type of systemic or local primary 
treatment for breast cancer. To facilitate response as-
sessment, patients were required to have a clinically 
palpable tumor of >2 cm, meeting the Response 
Evaluation Criteria for Solid Tumors (RECIST) for 
palpable measurable disease. Key exclusion criteria 
included inflammatory breast cancer, clinically sig-
nificant cardiac disease, and inadequate renal function. 
Treatments 
All eligible patients received four 21-day cycles of 
capecitabine 825 mg/m2 BID on days 1-14 plus do-
cetaxel 75 mg/m2 on day 1. This dosing regimen was 
selected on the basis of previous clinical studies of XT 
suggesting that doses can be reduced to improve tol-
erability without adversely affecting efficacy [24,26]. 
Patients with HER2-positive tumors determined by 
fluorescence in situ hybridization (FISH) also received 
a trastuzumab 4 mg/kg loading dose (90-minute infu-
sion) on day 1 followed by 2 mg/kg weekly (30-minute 
infusion) for 11 doses (Figure 2). An Independent Data 
Monitoring Board evaluated the safety and initial ef-
ficacy after treatment of a predetermined number of 
patients. Based on their analysis of the data, the trial 
was allowed to continue with no change to treatment 
doses and schedules; a change in the efficacy endpoint 
to pCR plus npCR was suggested. 
Primary and Secondary End Points 
The primary endpoint for the study was the rate 
of pCR plus npCR (residual T1a) in the affected breast 
after 4 cycles of preoperative therapy, determined by 
pathologic assessment of the resected specimen at the 
time of definitive surgery. A hematoxylin and eosin 
stained slide from each of the paraffin blocks prepared 
from the breast tissue and lymph nodes was reviewed 
at a central laboratory (Albany Medical College De-
partment of Pathology and Laboratory Medicine, New 
York, NY) to establish the presence or absence of infil-
trating breast cancer. Absence of histological evidence 
of invasive breast cancer cells defined pCR; npCR was 
defined as the presence of invasive tumor ≤5 mm 
(T1a). While pCR and npCR appear to have equivalent 
power to predict long-term survival [13], the sum of 
these endpoints has the advantage of providing a 
greater number of informative events, which is a par-
ticularly important consideration for the complemen-
tary correlative studies described below. 
Secondary clinical endpoints defined for the 
study included pCR and npCR as individual efficacy Int. J. Med. Sci. 2008, 5 
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parameters, ORR (according to RECIST), rates of local 
recurrence, DFS, OS, safety profile (assessed using 
National Cancer Institute Common Terminology Cri-
teria for Adverse Events, version 3.0), and quality of 
life (measured by the Functional Assessment of Cancer 
Therapy – Breast before, during, and at the completion 
of preoperative therapy). 
 
 
Figure 2: Treatment schedule. 
 
Correlative Studies 
Blood and tissue biomarker levels and candidate 
gene expression were measured prior to preoperative 
therapy and at the time of surgery to identify predic-
tive factors associated with pathologic response to XT 
or HXT. Potential biomarkers include TP, thymidine 
synthase (TS), and dihydropyrimidine dehydrogenase 
(DPD) for capecitabine and Tau protein for taxanes. 
Circulating tumor cell (CTC) levels were determined 
using the CellSearch System (Veridex, LLC., Warren, 
NJ) prior to the first treatment cycle and prior to de-
finitive surgery in patients with HER2 positive tumors. 
An interim analysis confirmed that CTCs were de-
tectable in patients in this study. Microarray analysis 
(AmpliChip p53 test; Roche Diagnostics, Indianapolis, 
IN) was used to measure p53 gene mutation levels in 
tissue samples prior to treatment. Preliminary data 
showed that approximately half of patients expressed 
p53 mutations at diagnosis. 
Interim Analysis 
Baseline characteristics of 90 patients included in 
an interim analysis are shown in Table 1 [39]. The 
clinical response rates were 79% in HER2-negative and 
90% in HER2-positive breast cancer. The rate of pCR 
plus npCR was 52% in patients with HER2-positive 
BC. After four treatment cycles, mean tumor diameters 
were reduced by 55% and 61%, respectively, in the 
HER2-negative and HER2-positive groups. The most 
frequent adverse events were hematologic toxicities 
and hand-foot syndrome. There were no grade 4 ad-
verse events, treatment-related deaths, or clinical or 
subclinical cardiac events. Treatment was discontin-
ued because of toxicity in 15 patients (10%) and four 
patients progressed prior to surgery. 
 
 
Table 1. Characteristics of patients included in an interim 
analysis.  
Baseline characteristics  HER2-negative 
(N=67) 
HER2-positive 
(N=23) 
Median age, years (range)  52 (29-82)  52 (32-66) 
Estrogen receptor positive 44 (65%)  10 (43%) 
Mean tumor diameter, cm 5.5  5.6 
 Int. J. Med. Sci. 2008, 5 
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CONCLUSIONS 
XT and HXT are promising non-anthracycline 
regimens for the preoperative treatment of women 
with HER2-negative and HER2-positive breast cancer, 
respectively. The ongoing XeNA study, in which 
treatment was assigned based on centrally performed 
FISH analysis, is expected to provide further clinical 
evidence to support the high activity observed with 
these regimens in patients with LABC or MBC [17,36]. 
A particularly important feature of the XeNA study is 
the use of pCR plus npCR as the primary endpoint. 
This endpoint is justified by previous data showing 
that patients with T1a tumors have excellent long-term 
survival [12] and that pCR and npCR have equivalent 
predictive power [13]. In addition, by increasing the 
number of informative events, the sum of pCR and 
npCR will facilitate correlative studies designed to 
identify patients most likely to benefit from XT and 
HXT and may expedite the clinical evaluation of these 
novel preoperative regimens. The final analysis, in-
cluding data from these correlative studies specifically 
designed to identify predictive biomarkers associated 
with pathologic response, will be available in 2009. 
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